To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
Abroad (travel likely)RecruitingPHASE1
Conditions
Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer) · Pancreatic Ductal Adenocarcinoma (PDAC) · Hepatocellular Carcinoma (HCC) · Gastric Cancer (GC)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Peking Union Medical College Hospital, Beijing, China
Contact: Principal Investigator (Wenmin Wu, Prof.)Peking University Cancer Hospital, Beijing, China
Contact: Principal Investigator (Lin Shen, Prof.)